|
|
 |
|
Viewing report
|
|
|
|
Stakeholder Insight: Osteoporosis - Poor Disease Awareness and Patient Identification Hinder Market Growth
Datamonitor, Feb 2003, Pages: 228
Osteoporosis, with an estimated prevalent population of over 127 million in the seven major markets and valued at around $7 billion in 2002, presents a commercially attractive target for development.
This report identifies trends in current prescribing practices, investigates how drug treatment differs according to disease severity and highlights unmet needs in screening and diagnosis.
Scope of Report:
Analysis is based on a survey of 160 treating physicians in the seven major markets as well as in-depth interviews with osteoporosis opinion leaders
Detailed treatment trees show the proportion of patients screened, presented, diagnosed and receiving treatment, by disease severity and country
Assesses the use of combination therapy in key patient and physician populations. Gauges physician perception of R&D trends and potential of novel drugs
Identifies therapeutic and diagnostic unmet needs, highlights areas where stakeholder investment is vital to drive patient identification
Report Highlights:
Our primary research has identified strong variances in class and brand prescribing preferences among physicians, according to both disease severity and geography. Combination therapy is prescribed in the US, Japan, the UK, France and Spain, though not in Italy and Germany.
Just 10% of the prevalent population in the seven major markets are diagnosed and just over half of those are drug treated. Growth in this market depends on driving patient identification and diagnosis: potential barriers to growth include low disease awareness and limited access to and utilization of diagnostic tools.
Three trends in osteoporosis R&D have the potential to radically change treatment and expand the market: Serms in additional indications PTH/anabolic drugs in fracture patients and novel bisphosphonates in flexible dosing and delivery formulations.
Reasons to Purchase:
Target physicians more effectively, through an understanding of prescribing behavior by specialty and its influences
Understand differential treatment and unmet needs in key patient populations identified by sex and disease severity
Validate new product forecasting based on diagnosis and treatment rates, and potential uptake for a new product based on physician’s perceptions
Customers who bought this item also bought
Commercial Insight: Osteoporosis and HRT - HRT is down for the count, but can osteoporosis players pick up the pieces?
Commercial Insight: Osteoporosis and HRT - HRT is down for the count, but can osteoporosis players pick up the pieces?
Pipeline Insight: Osteoporosis - Intermittent Dosing and Multiple Indications Drive Market Growth
Evaluating Patient Information Needs: Developing a Business Model for Online Marketing
Harnessing Patient Power: Strategies For Speeding Drug Approval, Building And Retaining Market Share
Disease Management Dimensions Series
Stakeholder Opinions: HIV - Reaching the Untapped Patient Population
Addressing Patient Compliance: Targeted marketing driving a shift in focus from acquisition to retention
|
|
|
|
